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To quantitatively assess the effectiveness of proton therapy for individual patients, we developed a pro-
totype for an online platform for proton decision support (PRODECIS) comparing photon and proton
treatments on dose metric, toxicity and cost-effectiveness levels. An evaluation was performed with 23
head and neck cancer datasets.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 118 (2016) 281–285
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nd/4.0/).Due to the continuous development of new cancer treatments
and the sophistication of existing radiotherapy, it has become
increasingly challenging to identify the best treatment for a speci-
fic patient [1]. A multifactorial clinical decision support system
(CDSS) could help meet this challenge when combining clinical,
dosimetric and cost variables (e.g. information about the patient
or tumour) with expert knowledge (e.g. on a specific treatment
modality) to make a quantitative treatment comparison [2–7].
Such a tool would facilitate individualised radiotherapy treatment.
Given its favourable dose distribution, proton therapy is
expected to be less toxic and more effective than photon therapy
[8–10]. As a result, many oncology centres around the world have
introduced proton therapy over the last decade [11]. However,
planning studies show that not all patients would benefit from this
more expensive treatment [12,13]. Clinical data-exchange plat-
forms have been developed previously to justify patient stratifica-
tion for a fair and efficient use of the treatment [14–16]. However,its cost-effectiveness compared to conventional photon radiother-
apy is yet unevaluated for many cancers [17–19].
Dutch health authorities have agreed upon the need for a
model-based indication methodology to select patients eligible
for proton radiotherapy [20–22]. Supplementary Fig. 1 illustrates
a Dutch decision tree regarding proton therapy reimbursement. It
determines whether a patient is expected to benefit sufficiently
from proton therapy justifying reimbursement of the treatment
costs. For an effective and efficient evaluation of these aspects, a
CDSS is needed that supports the claimwhether or not proton ther-
apy is expected to have a clinical benefit in a given patient.
We postulate that such a CDSS should have at least three levels.
The first dosimetric level should evaluate whether a radiotherapy
plan meets predefined dosimetric threshold for a patient’s organs
at risk (OARs). The second toxicity level should estimate whether
the probability of radiation induced normal tissue toxicity for the
patient is different between different treatment plans. The third
cost-effectiveness level should evaluate if the extra costs for a cer-
tain increase in effectiveness does not exceed a threshold set by
society. The effectiveness is defined in quality-adjusted life years
(QALYs), which are calculated by estimating the quality and quan-
tity of life extended by a medical intervention [23].
282 Online proton decision support system for HNCTo this end, we developed an online, three-level photon vs. pro-
ton CDSS prototype named PRODECIS (PROton DECIsion Support).
In this study, we evaluated the system’s performance for patients
with head and neck cancer (HNC). Data are provided online on
www.cancerdata.org [24].Materials and methods
We designed a modular CDSS (Fig. 1) to support the decision
between proton and photon therapy. The systemwas implemented
in Java SE 7 (Oracle, Redwood Shores, CA, USA) and Matlab 2010b
(Mathworks, Natick, MA, USA) and designed to import photon and
proton treatment plans in DICOM-RT format. A PHP webform was
created to upload the data and additionally ask for clinical param-
eters of the complication models. All patient information and
results were anonymously stored in a MySQL Workbench 6.0
(Oracle, Redwood Shores, CA, USA) database.
Computation services were separated into three levels. On the
dosimetric level, we adopted in-house dose–volume histogram
(DVH) metrics calculation algorithms to extract mean doses from
both photon and proton plans. On the toxicity level, we used a
number of validated late toxicity prediction models using the
TRIPOD Type 4 standard [25] (e.g., regression models [23,26,27]).
On the cost-effectiveness level, we incorporated published Markov
models1 ([23]) to assess the QALY and costs of the treatment.Experimental setup
To test the system, we used datasets from a ROCOCO cohort of
25 HNC patients for whom both photon and proton plans were
available [13]. First, on the dosimetric level we computed the dose
to the supraglottis area, the superior pharyngeal constrictor muscle
(PCM), and the ipsi- and contralateral parotid glands. Then, on the
toxicity level we estimated the normal tissue complication proba-
bility (NTCP) for xerostomia and swallowing dysfunction at 6 and
12 months after therapy, using the models published in previous
work [23,26,27]. Since the parotid gland location was indicated
with left or right in the given datasets, we defined the ipsi- and
contralateral parotid glands as receiving higher or lower doses,
respectively. Finally, on the cost-effectiveness level we used a
Markov model constructed for HNC patients [23] with pre-
treatment RTOG grade 2-swallowing dysfunction and xerostomia.
The model is described in Supplementary Table 1.Threshold definition
For the purpose of treatment comparison, we collected various
thresholds to define clinical benefit. On the dose comparison level,
from expert opinions and literature, we defined a clinical benefit
when a plan met clinical, desirable OAR mean dose thresholds
being parotid gland <26 Gy, superior PCM <50 Gy and supraglottis
area <50 Gy [28–30].
On the toxicity level, based on the CTCAEv4.0 toxicity criteria,
we considered clinical benefit as a predicted reduction in probabil-
ity of grade 2+ toxicity of >10%. In addition, we used the definition
of a ‘‘complication profile” where, for each patient, the toxicity
probability reductions exceeding 5% were summed and clinical
benefit was set at a total reduction of 15% or more [31].
On the cost-effectiveness level, we set the acceptable cost per
additional QALY derived from the Markov model at €80,000. This
is the official threshold proposed in the Netherlands by the Dutch
Council for Public Health and Care [32].1 Available on www.predictcancer.org.Statistics
We used two-tailed Wilcoxon signed rank tests to determine
whether the differences between plans were significant. P-values
of less than 0.05 were considered significant.Results
System development
The PRODECIS prototype was successfully built on a pipelined
image processing framework [33] from within our institute. For
scaling purposes, each level of computations was encapsulated into
a module and was then installed identically in two parallel pipeli-
nes (A and B in Fig. 1). After the whole plan of a treatment was
transferred, the respective pipeline began computing. Once both
computation pipelines were done, the results were delivered to
the third pipeline, comparing the multilevel results with the
defined threshold per level. Finally, the comparison results were
emailed back to the user. From the 25 datasets, the calculations
did not succeed for two, due to DICOM compatibility issues. For
every patient, it took approximately five minutes for a computer
with standard specifications (Intel CoreTM i5-3210M CPU processor
with 2.5 GHz, 4 GB memory) to finish all given tasks.Experiment results
The system proved successful in the automatic evaluation of
proton treatment eligibility according to the model-based
approach and predefined thresholds. The number of cases where
proton therapy ranked higher as well as average outcomes for both
modalities are summarised in Supplementary Table 2. In Fig. 2, the
individual results are shown for toxicity and cost-effectiveness, rel-
ative to the defined thresholds.
On the dosimetric level, proton therapy significantly lowered
doses to the OARs, except for the superior PCM. For the latter, only
the proton plans stayed below the thresholds for 2 cases, whereas
these were 4, 5 or 12 when considering the supraglottis area, ipsi-
or contralateral glands, respectively.
On the toxicity level, proton therapy significantly reduced all
toxicities. On average, the probability of swallowing dysfunction
6 months after treatment was reduced from 37% to 28% and from
23% to 18% at 12 months. The probability of xerostomia was
reduced for all 23 cases after treatment: from 48% to 25% at
6 months and from 46% to 23% at 12 months. With combined tox-
icity thresholds, protons outperformed photons for 23 cases at
6 months and 21 cases at 12 months.
On the cost-effectiveness level, we observed an increase in
QALY for all the patients in their proton therapy plans, although
it was also significantly more expensive. Using the nationally
accepted criterion of €80,000 per QALY gained, proton therapy
was found to be cost-effective for 8 of the 23 patients.Discussion
We successfully developed and evaluated the PRODECIS proto-
type to comply with the Dutch model and added the option to eval-
uate cost-effectiveness. The study shows that, given nationally
accepted guidelines for 15% reduction of a complication profile
including swallowing dysfunction and xerostomia, all patients
would benefit from proton therapy after 6 months and 91% after
12 months, while 35% would be considered cost-effective at a
threshold of 80,000€ per gained QALY. Although a CDSS was previ-
ously applied [34,35], we have not found any application that
could make quantitative decision-making about photon vs. proton
therapy at three levels.
Fig. 1. A visualisation of the pipeline system which consists of 3 major pipelines.
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Fig. 2. Relative (to threshold of 15%) ‘‘complication profiles” after 12 and 6 months (left axis). Only complication predictions that were larger than 5% were included. Right
axis for relative (to threshold of €80,000) ICER (=D€/DQALY).
Q. Cheng et al. / Radiotherapy and Oncology 118 (2016) 281–285 283A key characteristic of the system is its parallel pipeline struc-
ture, which allows easy extension by reusing the modular code.
Another important feature is the dynamic selection of models
based on the tumour type. Such flexibility enables the system to
rapidly adapt to different user requests and incorporate new
insights from the oncology society. Provided the availability of rel-
evant prediction models, future studies could perform systematic
experiments to search for an optimal outcome among multiple
treatment options at any anatomical site. The third system feature
is its use of the Markov model. It consists of health stages in terms
of toxicity RTOG grade and translates toxicity probabilities into
transitions between health stages (Supplementary Fig. 2). Through
the transition of a patient’s health state after treatment, the model
estimates the costs and effects of the treatment. An adapted ver-
sion, referred to as micro-simulation, was developed to predict sur-
vival of patients with non-small-cell lung cancer [36]. A recently
published study [37] shows the same approach to estimate cost-
effectiveness of the use of spacers when treating prostate cancer.
Multiple advantages of using the PRODECIS CDSS are foreseen.
First, it provides the opportunity for a clinician to make a model-
based decision following the Dutch guidelines. Second, it allows
clinics to quantitatively prioritise the limited treatment slots and
allocate them to the patients expected to gain the most from pro-ton therapy [17,38]. Third, it quantifies clinical evidence for health
insurance policy development. Furthermore, it can help in evaluat-
ing the cost-effectiveness of deploying a new technology. A final
point to note is that consent for data-exchange to the proposed
online system can readily be asked from the patient who is being
considered for proton therapy and has a direct benefit of the re-
use of its data.
However, these advantages will only be achieved when the fol-
lowing concerns are addressed sufficiently. As the system is still in
an early stage, extension to a fully operational system offering user
management is required to account for audit trails, for instance. As
with the MISTIR platform, security measures for encrypted data
transfer are to be provided [14]. Furthermore, the system offers a
single-shot evaluation and currently lacks proper case manage-
ment to retrieve previous comparison outcomes for re-evaluation.
Similar to the ReCompare system [15], the PRODECIS platform
is targeted towards referring photon therapy centres, accepting
previously calculated photon treatment plans for comparisons.
However, PRODECIS also uses user-provided proton plans, whereas
ReCompare uses the proton plan generated by the operating proton
therapy centre (PTC) itself. Such service can optionally be provided
by the staff backing PRODECIS, but as the comparison is performed
automatically using standardised models and thresholds an inde-
284 Online proton decision support system for HNCpendent evaluation of plan quality and prediction of complication
rates is offered to other PTC’s as well.
A prerequisite for the automatic numerical evaluation of PRO-
DECIS is that the uploaded treatment plans should adhere to strict
protocols, specifying contours per tumour group. The use of
so-called ‘‘umbrella protocols” and international naming conven-
tion guidelines will facilitate data exchange in a reusable fashion
[39–42]. Although quality assurance methods are implemented,
such as contour name mapping, major violation of the protocol will
prohibit evaluation, requiring corrections by the user.
It is foreseen that with current efforts from both community as
well as industry, instead of calculations based on user-provided
treatment plans, automatic plan generation could be applied
[43,44]. As an alternative to automatic planning, the estimation
of DVH parameters might be reliable and fast, given a sufficiently
large historical database of patients with the best planning (as in
the study of photon therapy plan optimisation [45]). Patient-
selection using a comprehensive matching mechanism based on
essential patient characteristics including clinical aspects, tumour
location and organ distribution is considered to be incorporated
into the PRODECIS system as shown in Supplementary Fig. 3. This
will greatly improve the workflow, avoiding the resource-intensive
bottleneck of double treatment planning.
A critical factor of the model-based selection method is the
quality of the treatment plans under evaluation. Therefore, we
expect realistic clinical-grade (thus not ‘‘beyond-state-of-the-art”)
treatment plans that would be administered to the patient in real
practice. This means planning protocols need to be up-to-date and
in line with the technical possibilities of the treatment options. As
for the experiment, the published proton plans for 25 HNC patients
are not considered as current standard anymore. We have now
produced robust treatment plans (unpublished data), which pro-
duce not dramatically different but more realistic proton plans,
where in some cases the differences are clinically relevant. To fur-
ther evaluate the system, we will experiment with external data-
sets from different centres using different treatment techniques.
Furthermore, in the current prototype, the system only consid-
ered those toxicities for which reliable NTCP-models were avail-
able and that connected to the cost-effectiveness model.
Additional models can easily be added including more OARs such
as oral cavity, brainstem, or area postrema to predict acute and late
radiation-induced toxicities, which may likely be reduced by pro-
ton therapy as well and could mean that the cost-effectiveness of
protons will be underestimated. For instance, the first comparison
of IMRT versus IMPT among oropharyngeal cancer patients treated
with chemo-radiation in the MD-Anderson Cancer centre [46]
showed a significant decrease of required tube feeding during the
course of radiation when IMPT was used. In this regard, direct mea-
surement of QALY’s in prospective data registration programs is
needed to obtain better insight into the cost-effectiveness of pro-
tons. In addition, to maximise system utility, it is highly desirable
to use toxicity models that consider multiple stages. e.g. A reduc-
tion of grade 4–5 toxicities is of utmost clinical benefit, but the
number of patients is too low to train such a model reliably, which
requires international data pooling or rather distributed learning
systems [47–49].
The HNC Markov model adopted in this system depended on
acceptable costs, which vary from country to country and even
from hospital to hospital. It also depended on toxicity estimation
models that were regressed without patients’ biomedical data.
Furthermore, previous interventions such as surgery or
chemotherapy were not included in the system, which will bias
the complication predictions. Therefore, service at this level is a
proof of principle and not conclusive.
The next step will be to include genetic biomarkers of radio-
sensitivity to further improve the prediction of late toxicities[50,51]. We aim to continuously update the system with additional
models that apply to other diseases and are scalable to other coun-
tries. Finally, patient-specific data such as molecular information,
patient-reported outcomes and personal preference should be
incorporated to truly improve the level of personalisation in deci-
sion support systems.Conflict of interest
None.Acknowledgments
We thank MAASTRO’s software development team for their
support. Furthermore, we acknowledge the involvement of
colleagues from the clinic’s departments, the data management
team and treatment planning. The authors acknowledge financial
support from the EU 7th framework programme (ARTFORCE –
no. 257144, REQUITE – no. 601826), an NGI Pre-Seed Grant
(no. 93612005) and Kankeronderzoekfonds Limburg from the
Health Foundation Limburg.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2015.12.
029.
References
[1] Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin
P. Comparison of the effectiveness of radiotherapy with photons, protons and
carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol
2010;95:32–40.
[2] Lambin P, Roelofs E, Reymen B, et al. Rapid Learning health care in oncology –
an approach towards decision support systems enabling customised
radiotherapy. Radiother Oncol 2013;109:159–64.
[3] Pijls-Johannesma M, Grutters JP, Verhaegen F, Lambin P, De Ruysscher D. Do
we have enough evidence to implement particle therapy as standard
treatment in lung cancer? A systematic literature review. Oncologist
2010;15:93–103.
[4] Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle
therapy? Cost analysis of external beam radiotherapy with carbon-ions,
protons and photons. Radiother Oncol 2010;95:45–53.
[5] Lambin P, Petit SF, Aerts HJ, The ESTRO, Lecture Breur, et al. From population to
voxel-based radiotherapy: exploiting intra-tumour and intra-organ
heterogeneity for advanced treatment of non-small cell lung cancer.
Radiother Oncol 2009;2010:145–52.
[6] Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in
radiation oncology–multifactorial decision support systems. Nat Rev Clin
Oncol 2013;10:27–40.
[7] Lambin P, Zindler J, Vanneste B, et al. Modern clinical research: how rapid
learning health care and cohort multiple randomised clinical trials
complement traditional evidence based medicine. Acta Oncol 2015:1–12.
[8] Proton radiotherapy. Horizon scanning report. Health Council of the
Netherlands, 2009. Available from: http://www.gezondheidsraad.nl/sites/
default/files/summary_200917.pdf.
[9] Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Particle therapy in
lung cancer: where do we stand? Cancer Treat Rev 2008;34:259–67.
[10] Grutters JP, Abrams KR, de Ruysscher D, et al. When to wait for more evidence?
Real options analysis in proton therapy. Oncologist 2011;16:1752–61.
[11] Jermann M. Particle therapy statistics in 2014. Int J Part Ther 2015;2:50–4.
[12] Roelofs E, EngelsmanM, Rasch C, et al. Results of a multicentric in silico clinical
trial (ROCOCO): comparing radiotherapy with photons and protons for non-
small cell lung cancer. J Thorac Oncol 2012;7:165–76.
[13] van der Laan HP, van de Water TA, van Herpt HE. The potential of intensity-
modulated proton radiotherapy to reduce swallowing dysfunction in the
treatment of head and neck cancer: a planning comparative study. Acta Oncol
2013;52:561–9.
[14] Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges
involved in a framework for multicentric radiotherapy treatment planning
studies. Radiother Oncol 2010;97:567–71.
[15] Luhr A, Lock S, Roth K, et al. Concept for individualized patient allocation:
ReCompare–remote comparison of particle and photon treatment plans.
Radiat Oncol 2014;9:59.
Q. Cheng et al. / Radiotherapy and Oncology 118 (2016) 281–285 285[16] Lock S, Roth K, Skripcak T, et al. Implementation of a software for REmote
COMparison of PARticlE and photon treatment plans: ReCompare. Z Med Phys
2015;25:287–94.
[17] Bekelman JE, Asch DA, Tochner Z, et al. Principles and reality of proton therapy
treatment allocation. Int J Radiat Oncol Biol Phys 2014;89:499–508.
[18] Pijls-Johannesma MC, de Ruysscher DK, Dekker AL. Lambin P [Protons and ions
in the treatment of cancer; a systematic review of the literature]. Ned Tijdschr
Geneeskd 2006;150:2435–41.
[19] Grutters JP, Pijls-Johannesma M, Ruysscher DD, et al. The cost-effectiveness of
particle therapy in non-small cell lung cancer: exploring decision uncertainty
and areas for future research. Cancer Treat Rev 2010;36:468–76.
[20] Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection
of patients for radiotherapy with protons aiming at reduction of side effects:
the model-based approach. Radiother Oncol 2013;107:267–73.
[21] Widder J, van der Schaaf A, Lambin P, et al. The quest for evidence for proton
therapy: the model-based approach and precision medicine. Int J Radiat Oncol
Biol Phys 2015.
[22] Grau C. The model-based approach to clinical studies in particle radiotherapy–
a new concept in evidence based radiation oncology? Radiother Oncol
2013;107:265–6.
[23] Ramaekers BL, Grutters JP, Pijls-Johannesma M, Lambin P, Joore MA,
Langendijk JA. Protons in head-and-neck cancer: bridging the gap of
evidence. Int J Radiat Oncol Biol Phys 2013;85:1282–8.
[24] Cheng Q, Roelofs E, Ramaekers B, et al. Data from: development and evaluation
of an online three-level proton vs photon decision support prototype for head
and neck cancer – comparison of dose. Toxicity and Cost-Effectiveness. Cancer
Data 2015. http://dx.doi.org/10.17195/candat.2015.10.5.
[25] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a
multivariable prediction model for individual prognosis or diagnosis
(TRIPOD): the TRIPOD statement. Eur J Clin Invest 2015;45:204–14.
[26] Christianen ME, Schilstra C, Beetz I, et al. Predictive modelling for swallowing
dysfunction after primary (chemo)radiation: results of a prospective
observational study. Radiother Oncol 2012;105:107–14.
[27] Beetz I, Schilstra C, Burlage FR, et al. Development of NTCP models for head
and neck cancer patients treated with three-dimensional conformal
radiotherapy for xerostomia and sticky saliva: the role of dosimetric and
clinical factors. Radiother Oncol 2012;105:86–93.
[28] Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy
dose–volume effects on salivary gland function. Int J Radiat Oncol Biol Phys
2010;76:S58–63.
[29] Rancati T, Schwarz M, Allen AM, et al. Radiation dose–volume effects in the
larynx and pharynx. Int J Radiat Oncol Biol Phys 2010;76:S64–69.
[30] Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with
cancer of the oropharynx are significantly affected by the radiation therapy
dose to the superior and middle constrictor muscle: a dose–effect relationship.
Radiother Oncol 2007;85:64–73.
[31] Consensus document voor selectie van patiënten met een model-based
indicatie voor protonen therapie (Unpublished internal document). Landelijk
Platform Protonen Therapie (LPPT), 2015.
[32] Sensible and sustainable care. Council for Public Health and Care (RVZ), 2006.
Available from: http://www.raadrvs.nl/uploads/docs/Sensible_
and_sustainable_care.pdf.
[33] Van Soest J, Lustberg T, Grittner D, et al. Towards a semantic PACS: using
Semantic Web technology to represent imaging data. Stud Health Technol
Inform 2014;205:166–70.
[34] Seroussi B, Soulet A, Messai N, Laouenan C, Mentre F, Bouaud J. Patient clinical
profiles associated with physician non-compliance despite the use of a
guideline-based decision support system: a case study with OncoDoc2 using
data mining techniques. AMIA Annu Symp Proc 2012;2012:828–37.[35] Steele SR, Bilchik A, Johnson EK, et al. Time-dependent estimates of recurrence
and survival in colon cancer: clinical decision support system tool
development for adjuvant therapy and oncological outcome assessment. Am
Surg 2014;80:441–53.
[36] Bongers ML dRD, Oberije C, Lambin P, Uyl-de Groot CA, Belderbos J, Coupé
VHM. Calibration of a micro-simulation model to assess cost-effectiveness of
conventional and innovative chemoradiation schemes in non-small cell lung
cancer In process.
[37] Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et al. Spacers in
radiotherapy treatment of prostate cancer: is reduction of toxicity cost-
effective? Radiother Oncol 2015;114:276–81.
[38] Jakobi A, Bandurska-Luque A, Stutzer K, et al. Identification of patient benefit
from proton therapy for advanced head and neck cancer patients based on
individual and subgroup normal tissue complication probability analysis. Int J
Radiat Oncol Biol Phys 2015;92:1165–74.
[39] CancerData.org. EuroCAT Umbrella Protocol for NSCLC 2015 [cited 2015 6 Oct].
Available from: https://www.cancerdata.org/protocols/eurocat-umbrella-
protocol-nsclc.
[40] Meldolesi E, van Soest J, Dinapoli N, et al. An umbrella protocol for
standardized data collection (SDC) in rectal cancer: a prospective uniform
naming and procedure convention to support personalized medicine.
Radiother Oncol 2014;112:59–62.
[41] Melidis C, Bosch WR, Izewska J, et al. Global harmonization of quality
assurance naming conventions in radiation therapy clinical trials. Int J Radiat
Oncol Biol Phys 2014;90:1242–9.
[42] Santanam L, Hurkmans C, Mutic S, et al. Standardizing naming conventions in
radiation oncology. Int J Radiat Oncol Biol Phys 2012;83:1344–9.
[43] Voet PW, Dirkx ML, Breedveld S, Fransen D, Levendag PC, Heijmen BJ. Toward
fully automated multicriterial plan generation: a prospective clinical study. Int
J Radiat Oncol Biol Phys 2013;85:866–72.
[44] Kraan AC, van de Water S, Teguh DN. Dose uncertainties in IMPT for
oropharyngeal cancer in the presence of anatomical, range, and setup errors.
Int J Radiat Oncol Biol Phys 2013;87:888–96.
[45] Petit SF, Wu B, Kazhdan M, et al. Increased organ sparing using shape-based
treatment plan optimization for intensity modulated radiation therapy of
pancreatic adenocarcinoma. Radiother Oncol 2012;102:38–44.
[46] Frank SJ, Rosenthal DI, Ang K, et al. Gastrostomy Tubes Decrease by Over 50%
With Intensity Modulated Proton Therapy (IMPT) During the Treatment of
Oropharyngeal Cancer Patients: A Case-Control Study. Proceedings of the
American Society for Radiation Oncology 55th Annual Meeting ASTRO’s 55th
Annual Metting 2013;87.
[47] Deasy JO, Bentzen SM, Jackson A, et al. Improving normal tissue complication
probability models: the need to adopt a ‘‘data-pooling” culture. Int J Radiat
Oncol Biol Phys 2010;76:S151–154.
[48] Dekker A, Nalbantov G, Oberije C, et al. Multi-centric learning with a federated
IT infrastructure: application to 2-year lung-cancer survival prediction.
Radiother Oncol 2013 Mar;106:S193.
[49] Skripcak T, Belka C, Bosch W, et al. Creating a data exchange strategy for
radiotherapy research: towards federated databases and anonymised public
datasets. Radiother Oncol 2014;113:303–9.
[50] Fachal L, Gomez-Caamano A, Barnett GC, et al. A three-stage genome-wide
association study identifies a susceptibility locus for late radiotherapy toxicity
at 2q24.1. Nat Genet 2014;46:891–4.
[51] Barnett GC, Thompson D, Fachal L, et al. A genome wide association study
(GWAS) providing evidence of an association between common genetic
variants and late radiotherapy toxicity. Radiother Oncol 2014;111:178–85.
